KIAA1797 Inhibitors
Chemical inhibitors of KIAA1797 can function by engaging with various components of cellular signaling pathways that are essential for the protein's activity. Wortmannin and LY294002, as potent phosphoinositide 3-kinase (PI3K) inhibitors, can lead to the functional inhibition of KIAA1797 by disrupting the PI3K/AKT signaling axis, a pathway known to interact with KIAA1797. The inhibition of PI3K activity by these chemicals results in decreased phosphorylation and activation of AKT, which is a critical step for downstream signaling events that support KIAA1797 function. Similarly, Rapamycin, a well-known mTOR inhibitor, disrupts mTOR signaling, which is also a downstream target of PI3K/AKT. Given that mTOR signaling is intertwined with cellular processes where KIAA1797 plays a role, its inhibition can indirectly suppress KIAA1797's function.
Further down the line of signaling, PD98059 and U0126 target the MEK/ERK pathway by inhibiting MEK, which prevents the activation of ERK, a kinase that has been implicated in pathways involving KIAA1797. By inhibiting ERK phosphorylation, these compounds can indirectly reduce KIAA1797 activity. Other kinase inhibitors, such as SP600125 and SB203580, which target JNK and p38 MAP kinase respectively, can also attenuate signaling pathways that potentially engage KIAA1797, leading to its functional inhibition. Y-27632, by selectively inhibiting ROCK, affects the Rho/ROCK pathway, which can have downstream effects on the cellular functions involving KIAA1797. Src family kinases, which are the targets of Dasatinib and PP2, play roles in a myriad of cellular processes, and their inhibition can disrupt functions and signaling events that are necessary for KIAA1797 activity. Lastly, BIX 02189 and SL327, both targeting different components of the MAPK pathway (MEK5 and MEK1/2, respectively), provide a means to inhibit the activation of ERK5 and ERK1/2, which may be required for KIAA1797's activity, thereby leading to its functional inhibition.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent phosphoinositide 3-kinase (PI3K) inhibitor. KIAA1797 is known to interact with components of the PI3K pathway. By inhibiting PI3K, wortmannin can lead to reduced AKT phosphorylation, which is essential for the downstream signaling required for the function of KIAA1797. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor. It blocks PI3K activity, leading to decreased activation of AKT. Since KIAA1797 is involved in pathways associated with PI3K signaling, inhibition of PI3K by LY294002 can suppress the pathway's activity, indirectly leading to functional inhibition of KIAA1797. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can disrupt the mTOR signaling pathway, indirectly affecting functions associated with KIAA1797, as mTOR is a downstream target of PI3K/AKT, which is relevant to KIAA1797's function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which in turn inhibits ERK phosphorylation. Since KIAA1797 has been implicated in pathways involving ERK, inhibiting its activation can indirectly inhibit the functional activity of KIAA1797. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in stress-activated protein kinase pathways that could intersect with KIAA1797's function. Inhibition of JNK can thus indirectly inhibit signaling processes in which KIAA1797 is involved. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. p38 MAP kinase is involved in cellular stress responses and its inhibition can affect cellular functions related to KIAA1797. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of the Rho-associated protein kinase (ROCK). Since KIAA1797 can interact with proteins regulated by the Rho/ROCK pathway, inhibiting ROCK can potentially lead to functional inhibition of KIAA1797. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream regulators of ERK. By inhibiting MEK1/2, U0126 prevents the activation of ERK, which may be required for KIAA1797's activity, thus indirectly inhibiting KIAA1797. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinases inhibitor. Src kinases are involved in multiple signaling pathways, some of which could be necessary for KIAA1797 function. By inhibiting Src kinases, dasatinib can lead to indirect inhibition of KIAA1797. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. Similar to dasatinib, by inhibiting Src kinases, PP2 can interfere with signaling pathways that are associated with KIAA1797, potentially leading to its functional inhibition. | ||||||